Fig. 1 · Structure

Documents & Downloads

Entrectinib

Cat. No. A15801 CAS 1108743-60-7

TRK, ROS1, ALK inhibitor

Entrectinib, also known as RXDX-101 and NMS-E628, is an oral small molecule inhibitor of TrkA, TrkB and TrkC, as well as ROS1 and ALK, with high potency and selectivity.

In Stock

Publications for Entrectinib

1 publication citing this product

  1. Angelina T Regua, .et al. , Cancer Lett, 2024, Jun 7:597:217023 PMID: 38852701

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Entrectinib reduced BDNF-stimulated TRKB phosphorylation in engineered neuroblastoma cells. The concentration required for near-complete suppression differed between the SY5Y-TRKB and NLF-TRKB models. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
TrkA
TrkB
TrkC
ROS1
ALK

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 7.46 μM Antiproliferative activity against EGFR-positive human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay [PMID: 34534734]
BaF3 IC50 0.003 μM Inhibition of human TEL (336 residues) fused-TRKA (440 to 796 residues) (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay [PMID: 27003761]
BaF3 IC50 0.003 μM Inhibition of human TEL (336 residues) fused-TRKB (455 to 822 residues) (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay [PMID: 27003761]
BaF3 IC50 0.003 μM Inhibition of human TEL (336 residues) fused-TRKC (454 to 825 residues) (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay [PMID: 27003761]
BaF3 IC50 0.005 μM Inhibition of human TEL (336 residues) fused-ROS1 (1891 to 2347 residues) (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay [PMID: 27003761]
BaF3 IC50 0.028 μM Inhibition of wild type EML4-ALK (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay [PMID: 27003761]
BaF3 IC50 0.067 μM Inhibition of EML4-ALK L1196M mutant (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay [PMID: 27003761]
BaF3 IC50 0.897 μM Inhibition of EML4-ALK G1202R mutant (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by cell titer-glo assay [PMID: 27003761]
BaF3 IC50 2.104 μM Cytotoxicity against mouse IL-3 dependent BA/F3 cells incubated for 72 hrs by cell titer-glo assay [PMID: 27003761]
KARPAS-299 IC50 0.031 μM Antiproliferative activity against human KARPAS299 cells incubated for 72 hrs by cell titer-glo assay [PMID: 27003761]
KARPAS-299 IC50 0.076 μM Antiproliferative activity against NPM-ALK addicted human KARPAS-299 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay [PMID: 34534734]
KARPAS-299 IC50 31 nM Antiproliferative activity against human KARPAS299 cells incubated for 48 hrs by sulforhodamine B assay [PMID: 31077998]
KM12 IC50 0.0017 μM Antiproliferative activity against human KM12 cells after 72 hrs [PMID: 30188734]
KM12 IC50 0.012 μM Cytotoxicity against human KM12 cells assessed as reduction in cell viability incubated for 72 hrs by resazurin based assay [PMID: 33652352]
KM12 IC50 0.017 μM Antiproliferative activity against human KM12 cells expressing TRKA protein incubated for 72 hrs by cell titer-glo assay [PMID: 27003761]
KM12 IC50 0.057 μM Antiproliferative activity against TPM3-NTRK1-addicted human KM12 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay [PMID: 34534734]
KM12 IC50 17 nM Antiproliferative activity against human KM12 cells incubated for 48 hrs by sulforhodamine B assay [PMID: 31077998]
KM12 IC50 4.3 nM Antiproliferative activity against human KM12 cells expressing TPM3-TRKA assessed as reduction in cell viability measured after 3 days by Celltiter-Glo assay [PMID: 32550985]
MV4-11 IC50 0.081 μM Antiproliferative activity against human MV411 cells incubated for 72 hrs by cell titer-glo assay [PMID: 27003761]

19 records · Scroll to view more

Entrectinib Research Summary

This section summarizes 1 in vitro study and 2 in vivo studies of Entrectinib from 2 published references. In vitro models include SH-SY5Y-TRKB clone BR6 and NLF-TRKB clone 6 neuroblastoma cells. In vivo models include BT474-TtzmR mammary-fat-pad xenografts in female athymic nude mice; BCM-3887 basal-subtype breast cancer PDX in female athymic nude mice.

Entrectinib In Vitro Studies

Cellular TRKB phosphorylation in engineered neuroblastoma models

Cell-based study · SH-SY5Y-TRKB clone BR6 and NLF-TRKB clone 6 neuroblastoma cells [1]

Entrectinib reduced BDNF-induced TRKB phosphorylation. The authors describe almost complete inhibition at 10 nM in SY5Y-TRKB and at 50 nM in NLF-TRKB; these are treatment concentrations, not IC50 values.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
SY5Y-TRKB BDNF-induced TRKB phosphorylationQualitative immunoblot response Almost complete inhibition at 10 nM[1]
NLF-TRKB BDNF-induced TRKB phosphorylationQualitative immunoblot response Almost complete inhibition at 50 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Figure 1A: 1, 5, 10, 20, 30, 40, 50, 100 and 200 nM; Figure 2A: 1, 10, 50 and 100 nM.
Exposure duration
1 h drug exposure before BDNF stimulation for 15 min (Methods 2.4).
Method
Western blot of phosphorylated TRK and signaling proteins; BDNF 100 ng/mL; no-BDNF and BDNF-without-drug controls. Pan-TRK, total AKT and actin controls are shown in Figure 1A; actin in Figure 2A.
Vehicle
DMSO stock (Methods 2.1); final DMSO fraction not reported in acquired main methods.
Reported limits
Methods 2.4 states 10–200 nM, whereas Figures 1A/2A include 1 nM. Panel-specific tested concentrations are retained; no exact inhibitory percentage or IC50 is inferred.
Methods and source locations

Compound reported in the paper: Entrectinib; Compound label in the paper: RXDX-101

Findings concern the reported research material in engineered neuroblastoma cells; no Adooq lot validation.

Methods 2.1, 2.2, 2.4 and 2.8; Results 3.1; Figures 1A and 2A with captions

SY5Y-TRKB BDNF-induced TRKB phosphorylation: Western blot; authors’ qualitative description, checked against the corresponding viewed panel. — Figure 1A; Results 3.1

NLF-TRKB BDNF-induced TRKB phosphorylation: Western blot; authors’ qualitative description, checked against the corresponding viewed panel. — Figure 2A; Results 3.1

Entrectinib In Vivo Studies

In orthotopic breast cancer models, entrectinib plus pacritinib suppressed tumor growth. Entrectinib alone did not significantly suppress BT474-TtzmR xenograft growth, but did suppress growth of BCM-3887 PDX tumors versus vehicle. These responses are specific to the tested models and regimens. [2]

HER2-positive trastuzumab-refractory orthotopic xenografts

Animal study · BT474-TtzmR mammary-fat-pad xenografts in female athymic nude mice [2]

Combination treatment suppressed tumor growth versus vehicle and single agents; neither single agent significantly altered tumor growth or endpoint tumor mass.

Conditions shared by the study groups

Route
Oral
Frequency
Twice daily, 5 days/week
Treatment course
From day 9 to study endpoint (day 35 shown).
Vehicle
100% PEG
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle—Reference tumor-growth group.[2]
Entrectinib
25 mg/kg
Vehicle groupNo significant suppression of tumor growth or endpoint tumor mass versus vehicle.[2]
Pacritinib
50 mg/kg
Vehicle groupNo significant suppression of tumor growth versus vehicle.[2]
Entrectinib + pacritinib
Entrectinib 25 mg/kg + pacritinib 50 mg/kg
Vehicle and the two single-agent groupsSignificant suppression of tumor growth versus vehicle and single agents.[2]
Vehicle
Model: BT474-TtzmR mammary-fat-pad xenografts in female athymic nude mice
Reported limits: No lot or salt designation. Vehicle composition beyond 100% PEG not specified in acquired main text.
Entrectinib
Model: BT474-TtzmR mammary-fat-pad xenografts in female athymic nude mice
Reported limits: No lot or salt designation. Vehicle composition beyond 100% PEG not specified in acquired main text.
Pacritinib
Model: BT474-TtzmR mammary-fat-pad xenografts in female athymic nude mice
Reported limits: No lot or salt designation. Vehicle composition beyond 100% PEG not specified in acquired main text.
Entrectinib + pacritinib
Model: BT474-TtzmR mammary-fat-pad xenografts in female athymic nude mice
Reported limits: No lot or salt designation. Vehicle composition beyond 100% PEG not specified in acquired main text.
Methods and source locations

Compound reported in the paper: Entrectinib; Compound label in the paper: Entrectinib alone or with pacritinib

Supplier attribution applies to the paper; the tested lot and form have not been established as SKU A15801.

Methods 2.2; Results 3.4; Figure 4A–C and caption

Vehicle · Methods 2.2; Results 3.4; Figure 4A–C and caption

Entrectinib · Methods 2.2; Results 3.4; Figure 4A–C and caption

Pacritinib · Methods 2.2; Results 3.4; Figure 4A–C and caption

Entrectinib + pacritinib · Methods 2.2; Results 3.4; Figure 4A–C and caption

Basal breast cancer patient-derived orthotopic xenografts

Animal study · BCM-3887 basal-subtype breast cancer PDX in female athymic nude mice [2]

Combination treatment produced the slowest tumor growth. Entrectinib monotherapy significantly suppressed growth versus vehicle, whereas pacritinib monotherapy did not.

Conditions shared by the study groups

Route
Oral gavage
Frequency
Twice daily, 5 days/week
Treatment course
From day 21 to study endpoint (day 35 shown).
Vehicle
100% PEG
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle—Reference tumor-growth group.[2]
Entrectinib
25 mg/kg
Vehicle groupSignificant suppression of tumor growth versus vehicle.[2]
Pacritinib
50 mg/kg
Vehicle groupNo significant suppression of tumor growth versus vehicle.[2]
Entrectinib + pacritinib
Entrectinib 25 mg/kg + pacritinib 50 mg/kg
Vehicle and the two single-agent groupsSlowest tumor growth among the four groups; suppressed versus vehicle.[2]
Vehicle
Model: BCM-3887 basal-subtype breast cancer PDX in female athymic nude mice
Reported limits: No lot or salt designation. Vehicle composition beyond 100% PEG not specified in acquired main text.
Entrectinib
Model: BCM-3887 basal-subtype breast cancer PDX in female athymic nude mice
Reported limits: No lot or salt designation. Vehicle composition beyond 100% PEG not specified in acquired main text.
Pacritinib
Model: BCM-3887 basal-subtype breast cancer PDX in female athymic nude mice
Reported limits: No lot or salt designation. Vehicle composition beyond 100% PEG not specified in acquired main text.
Entrectinib + pacritinib
Model: BCM-3887 basal-subtype breast cancer PDX in female athymic nude mice
Reported limits: No lot or salt designation. Vehicle composition beyond 100% PEG not specified in acquired main text.
Methods and source locations

Compound reported in the paper: Entrectinib; Compound label in the paper: Entrectinib alone or with pacritinib

Supplier attribution applies to the paper; the tested lot and form have not been established as SKU A15801.

Methods 2.2; Results 3.5; Figure 5A–D and caption

Vehicle · Methods 2.2; Results 3.5; Figure 5A, D and caption

Entrectinib · Methods 2.2; Results 3.5; Figure 5A, D and caption

Pacritinib · Methods 2.2; Results 3.5; Figure 5A, D and caption

Entrectinib + pacritinib · Methods 2.2; Results 3.5; Figure 5A, D and caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1108743-60-7
Applications TRK, ROS1, ALK inhibitor
Formula C31H34F2N6O2
Molecular Weight 560.64
Synonyms RXDX-101; NMS E628
SMILES
CN1CCN(CC1)C2=CC(=C(C=C2)C(=O)NC3=NNC4=C3C=C(C=C4)CC5=CC(=CC(=C5)F)F)NC6CCOCC6

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 89 mg/mL (158.74 mM)
Water Insoluble
Ethanol 67 mg/mL (119.5 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Entrectinib Research References

  1. [1] Iyer R, Wehrmann L, Golden RL, et al. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model Cancer Letters (2016). PMID: 26797418 DOI: 10.1016/j.canlet.2016.01.018 Source material
  2. [2] Regua AT, Bindal S, Najjar MK, et al. Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers Cancer Letters (2024). PMID: 38852701 DOI: 10.1016/j.canlet.2024.217023 Source material

Publications

1 publication citing this product

  1. Angelina T Regua, .et al. , Cancer Lett, 2024, Jun 7:597:217023 PMID: 38852701

Added to your cart

View Cart Checkout
Loading...